Coloma Jason V sold $1.0M of MAZE (indirect holdings)
Coloma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $29.98 ($29.95–$30.44, $1.03M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This is a planned open-market sale of 34,501 shares (about $1.03M) with holdings after the transaction of 287,171 shares. No new company fundamentals are disclosed.
Market read
Traders may monitor for follow-on insider activity, but the 10b5-1 framing reduces the likelihood of a durable negative repricing from this single filing.
What to watch
The sale is indirect and executed across multiple trades; without context on total planned volume and any concurrent insider buys, the signal strength is weak.
Background
The article is an SEC Form 4 disclosure of an insider transaction by Maze Therapeutics CEO Coloma Jason V, executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Maze Therapeutics CEO Coloma Jason V sold about $1.03M of MAZE shares via a 10b5-1 plan on July 1 at ~$29.98 average.
Near-term impact likely limited; any reaction should fade unless accompanied by other company-specific news.
The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, and the article provides no new operational, financial, or regulatory catalyst beyond the sale.
Market effects
Minimal; single-company insider sale without accompanying sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s view of near-term valuation risk, so traders may treat it as a mild sentiment headwind.
Key entities
- issuerMaze Therapeutics, Inc.
Subject of the Form 4 insider transaction; CEO sold shares under a 10b5-1 plan.
- insiderColoma Jason V
CEO and officer/director who executed the planned sale.